"An assessment of the preliminary data on the composite primary endpoint indicates that there were 13.4 percent more patients whose condition remained stable or improved on Fibrillex(TM) compared to placebo (p-value of 0.06). However, Fibrillex(TM) did not achieve the study's pre-specified p-value of 0.01 on the primary endpoint."
Anyone guess why the threshold (p<0.01) was so high ?
Market Data 
Markets 
AI
